FDA Warning Letter Snuffs Out Boehringer's Atrovent/Combivent Ads
This article was originally published in The Pink Sheet Daily
Executive Summary
The ad, which features birthday candles being blown out, makes unsubstantiated effectiveness claims, an FDA warning letter states. Boehringer Ingelheim said the ad is no longer in use; the company plans to distribute corrective information.
You may also be interested in...
Micardis Promotion Cited By FDA For Superiority Claims Over Norvasc, Diovan
References included in a Boehringer Ingelheim sales aid for Micardis do not provide sufficient evidence or clinical experience to support the superiority claims, an FDA ad division "untitled" letter states. The agency also cites the sales aid for including unsubstantiated efficacy claims and omitting risk information.
Micardis Promotion Cited By FDA For Superiority Claims Over Norvasc, Diovan
References included in a Boehringer Ingelheim sales aid for Micardis do not provide sufficient evidence or clinical experience to support the superiority claims, an FDA ad division "untitled" letter states. The agency also cites the sales aid for including unsubstantiated efficacy claims and omitting risk information.
Viramune Print Ad Cited By FDA For Risk Minimization
Boxed text providing risk information for the HIV therapy uses print that is too small and omits necessary statements, FDA's ad division says. Boehringer Ingelheim must present FDA with a plan to discontinue using the ad by Oct. 6.